DOCSLIB.ORG

Renal Artery Stenosis Management Strategies: an Updated Comparative Effectiveness Review Comparative Effectiveness Review Number 179

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Renal Artery Stenosis Management Strategies: an Updated Comparative Effectiveness Review Comparative Effectiveness Review Number 179 Comparative Effectiveness Review Number 179 Renal Artery Stenosis Management Strategies: An Updated Comparative Effectiveness Review Comparative Effectiveness Review Number 179 Renal Artery Stenosis Management Strategies: An Updated Comparative Effectiveness Review Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. 290-2015-00002-I Prepared by: Brown Evidence-based Practice Center Providence, RI Investigators: Ethan M. Balk, M.D., M.P.H. Gowri Raman, M.D., M.S. Gaelen P. Adam, M.L.I.S. Christopher W. Halladay, B.A., Sc.M. Valerie N. Langberg, Sc.M. Ijeoma A. Azodo, M.D., Ch.M. Thomas A. Trikalinos, M.D., Ph.D. AHRQ Publication No. 16-EHC026-EF August 2016 This report is based on research conducted by the Brown Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-2015-00002-I). The findings and conclusions in this document are those of the authors, who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. None of the investigators have any affiliations or financial involvement that conflicts with the material presented in this report. The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information, i.e., in the context of available resources and circumstances presented by individual patients. This report is made available to the public under the terms of a licensing agreement between the author and the Agency for Healthcare Research and Quality. This report may be used and reprinted without permission except those copyrighted materials that are clearly noted in the report. Further reproduction of those copyrighted materials is prohibited without the express permission of copyright holders. AHRQ or U.S. Department of Health and Human Services endorsement of any derivative products that may be developed from this report, such as clinical practice guidelines, other quality enhancement tools, or reimbursement or coverage policies, may not be stated or implied. This report may periodically be assessed for the currency of conclusions. If an assessment is done, the resulting surveillance report describing the methodology and findings will be found on the Effective Health Care Program Web site at www.effectivehealthcare.ahrq.gov. Search on the title of the report. Persons using assistive technology may not be able to fully access information in this report. For assistance contact [email protected]. Suggested citation: Balk EM, Raman G, Adam GP, Halladay CW, Langberg VN, Azodo IA, Trikalinos TA. Renal Artery Stenosis Management Strategies: An Updated Comparative Effectiveness Review. Comparative Effectiveness Review No. 179. (Prepared by the Brown Evidence-based Practice Center under Contract No. 290-2015-00002-I.) AHRQ Publication No. 16-EHC026-EF. Rockville, MD: Agency for Healthcare Research and Quality; August 2016. www.effectivehealthcare.ahrq.gov/reports/final.cfm. ii Preface The Agency for Healthcare Research and Quality (AHRQ), through its Evidence-based Practice Centers (EPCs), sponsors the development of systematic reviews to assist public- and private-sector organizations in their efforts to improve the quality of health care in the United States. These reviews provide comprehensive, science-based information on common, costly medical conditions, and new health care technologies and strategies. Systematic reviews are the building blocks underlying evidence-based practice; they focus attention on the strength and limits of evidence from research studies about the effectiveness and safety of a clinical intervention. In the context of developing recommendations for practice, systematic reviews can help clarify whether assertions about the value of the intervention are based on strong evidence from clinical studies. For more information about AHRQ EPC systematic reviews, see www.effectivehealthcare.ahrq.gov/reference/purpose.cfm. AHRQ expects that these systematic reviews will be helpful to health plans, providers, purchasers, government programs, and the health care system as a whole. Transparency and stakeholder input are essential to the Effective Health Care Program. Please visit the Web site (www.effectivehealthcare.ahrq.gov) to see draft research questions and reports or to join an email list to learn about new program products and opportunities for input. If you have comments on this systematic review, they may be sent by mail to the Task Order Officer named below at: Agency for Healthcare Research and Quality, 5600 Fishers Lane, Rockville, MD 20857, or by email to [email protected]. Andrew Bindman, M.D. Arlene S. Bierman, M.D., M.S. Director Director Agency for Healthcare Research and Quality Center for Evidence and Practice Improvement Agency for Healthcare Research and Quality Stephanie Chang, M.D., M.P.H. Elise Berliner, Ph.D. Director Task Order Officer Evidence-based Practice Center Program Center for Evidence and Practice Improvement Center for Evidence and Practice Improvement Agency for Healthcare Research and Quality Agency for Healthcare Research and Quality iii Technical Expert Panel In designing the study questions and methodology at the outset of this report, the EPC consulted several technical and content experts. Broad expertise and perspectives were sought. Divergent and conflicted opinions are common and perceived as healthy scientific discourse that results in a thoughtful, relevant systematic review. Therefore, in the end, study questions, design, methodologic approaches, and/or conclusions do not necessarily represent the views of individual technical and content experts. Technical Experts must disclose any financial conflicts of interest greater than $10,000 and any other relevant business or professional conflicts of interest. Because of their unique clinical or content expertise, individuals with potential conflicts may be retained. The TOO and the EPC work to balance, manage, or mitigate any potential conflicts of interest identified. The list of Technical Experts who provided input to this report follows: Richard Cambria, M.D. Diane Reid, M.D.* Harvard Medical School National Institutes of Health Cambridge, MA Bethesda, MD Kenneth Cavanaugh, Ph.D.* John H. Rundback, M.D., FAHA, FSVM, U.S Food and Drug Administration FSIR* Silver Spring, MD Holy Name Medical Center Teaneck, NJ Matthew Corriere, M.D., M.S.* Wake Forest University School of Medicine Stephen C. Textor, M.D., FAHA* Winston-Salem, NC Mayo Clinic Rochester, MN Joseph Nally, Jr., M.D.* Cleveland Clinic Katherine Tuttle, M.D., FACP, FASN* Cleveland, OH Providence Health Care and University of Washington School of Medicine Jeffrey Olin, M.D. Spokane, WA Icahn School of Medicine at Mount Sinai New York, NY Jonathan Winston, M.D., FAHA, FSVM, FSIR Holy Name Medical Center Teaneck, NJ *Provided input on Draft Report. iv Peer Reviewers Prior to publication of the final evidence report, EPCs sought input from independent Peer Reviewers without financial conflicts of interest. However, the conclusions and synthesis of the scientific literature presented in this report do not necessarily represent the views of individual reviewers. Peer Reviewers must disclose any financial conflicts of interest greater than $10,000 and any other relevant business or professional conflicts of interest. Because of their unique clinical or content expertise, individuals with potential nonfinancial conflicts may be retained. The TOO and the EPC work to balance, manage, or mitigate any potential nonfinancial conflicts of interest identified. The list of Peer Reviewers follows: Matthew Edwards, M.D. Wake Forest Baptist Medical Center Winston-Salem, NC Sanjay Misra, M.D., FSIR, FAHA Mayo Clinic Rochester, MN Christopher White, M.D., FACC, FAHA, MSCAI, FESC Ochsner Medical Center New Orleans, LA v Renal Artery Stenosis Management Strategies: An Updated Comparative Effectiveness Review Structured Abstract Background. Treatment options for atherosclerotic renal artery stenosis (ARAS) include medical therapy alone or renal artery revascularization with continued medical therapy, most commonly by percutaneous transluminal renal angioplasty with stent placement (PTRAS). This review updates a prior Comparative Effectiveness Review of management strategies for ARAS from 2006, which was updated in 2007. Objectives. Compare the effectiveness and safety of PTRAS versus medical therapy, and also versus surgical revascularization, to treat ARAS. Identify predictors of outcomes by intervention. Data sources. MEDLINE®, Embase®, the Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews from inception to March 16, 2016; eligible studies from the original reports and other relevant existing systematic reviews; and other sources. Review methods. We included studies comparing ARAS
Load more

Recommended publications
  • Impact of Urolithiasis and Hydronephrosis on Acute Kidney Injury in Patients with Urinary Tract Infection
    bioRxiv preprint doi: https://doi.org/10.1101/2020.07.13.200337; this version posted July 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Impact of urolithiasis and hydronephrosis on acute kidney injury in patients with urinary tract infection Short title: Impact of urolithiasis and hydronephrosis on AKI in UTI Chih-Yen Hsiao1,2, Tsung-Hsien Chen1, Yi-Chien Lee3,4, Ming-Cheng Wang5,* 1Division of Nephrology, Department of Internal Medicine, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chia-Yi, Taiwan 2Department of Hospital and Health Care Administration, Chia Nan University of Pharmacy and Science, Tainan, Taiwan 3Department of Internal Medicine, Fu Jen Catholic University Hospital, Fu Jen Catholic University, New Taipei, Taiwan 4School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei, Taiwan 5Division of Nephrology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan *[email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.07.13.200337; this version posted July 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Abstract Background: Urolithiasis is a common cause of urinary tract obstruction and urinary tract infection (UTI). This study aimed to identify whether urolithiasis with or without hydronephrosis has an impact on acute kidney injury (AKI) in patients with UTI.
    [Show full text]
  • The Links Between Microbiome and Uremic Toxins in Acute Kidney Injury: Beyond Gut Feeling—A Systematic Review
    toxins Article The Links between Microbiome and Uremic Toxins in Acute Kidney Injury: Beyond Gut Feeling—A Systematic Review Alicja Rydzewska-Rosołowska 1,* , Natalia Sroka 1, Katarzyna Kakareko 1, Mariusz Rosołowski 2 , Edyta Zbroch 1 and Tomasz Hryszko 1 1 2nd Department of Nephrology and Hypertension with Dialysis Unit, Medical University of Białystok, 15-276 Białystok, Poland; [email protected] (N.S.); [email protected] (K.K.); [email protected] (E.Z.); [email protected] (T.H.) 2 Department of Gastroenterology and Internal Medicine, Medical University of Białystok, 15-276 Białystok, Poland; [email protected] * Correspondence: [email protected] Received: 30 October 2020; Accepted: 9 December 2020; Published: 11 December 2020 Abstract: The last years have brought an abundance of data on the existence of a gut-kidney axis and the importance of microbiome in kidney injury. Data on kidney-gut crosstalk suggest the possibility that microbiota alter renal inflammation; we therefore aimed to answer questions about the role of microbiome and gut-derived toxins in acute kidney injury. PubMed and Cochrane Library were searched from inception to October 10, 2020 for relevant studies with an additional search performed on ClinicalTrials.gov. We identified 33 eligible articles and one ongoing trial (21 original studies and 12 reviews/commentaries), which were included in this systematic review. Experimental studies prove the existence of a kidney-gut axis, focusing on the role of gut-derived uremic toxins and providing concepts that modification of the microbiota composition may result in better AKI outcomes. Small interventional studies in animal models and in humans show promising results, therefore, microbiome-targeted therapy for AKI treatment might be a promising possibility.
    [Show full text]
  • Risk of Renal Function Decline in Patients with Ketamine-Associated Uropathy
    International Journal of Environmental Research and Public Health Article Risk of Renal Function Decline in Patients with Ketamine-Associated Uropathy Shih-Hsiang Ou 1,2,3, Ling-Ying Wu 4, Hsin-Yu Chen 1,2, Chien-Wei Huang 1,2, Chih-Yang Hsu 1,2, Chien-Liang Chen 1,2 , Kang-Ju Chou 1,2, Hua-Chang Fang 1,2 and Po-Tsang Lee 1,2,* 1 Division of Nephrology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan; [email protected] (S.-H.O.); [email protected] (H.-Y.C.); [email protected] (C.-W.H.); [email protected] (C.-Y.H.); [email protected] (C.-L.C.); [email protected] (K.-J.C.); [email protected] (H.-C.F.) 2 Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei 112, Taiwan 3 Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan 4 Department of Obstetrics and Gynecology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 833, Taiwan; [email protected] * Correspondence: [email protected]; Tel.: +886-7342-2121 (ext. 8090) Received: 8 August 2020; Accepted: 29 September 2020; Published: 4 October 2020 Abstract: Ketamine-associated diseases have been increasing with the rise in ketamine abuse. Ketamine-associated uropathy is one of the most common complications. We investigated the effects of ketamine-associated uropathy on renal health and determined predictors of renal function decline in chronic ketamine abusers. This retrospective cohort study analyzed 51 patients (22 with ketamine- associated hydronephrosis and 29 with ketamine cystitis) from Kaohsiung Veterans General Hospital in Taiwan.
    [Show full text]
  • Original Article Thrombocytopenia As a Predictor of Acute Kidney Injury in Patients with Emphysematous Pyelonephritis
    Int J Clin Exp Med 2019;12(1):849-854 www.ijcem.com /ISSN:1940-5901/IJCEM0078347 Original Article Thrombocytopenia as a predictor of acute kidney injury in patients with emphysematous pyelonephritis Heng Fan1,3*, Yu Zhao2*, Min Sun1, Jian-Hua Zhu1 1Department of Intensive Care Unit, Ningbo First Hospital, Ningbo, PR China; 2Department of Nephrology, Ningbo Urology and Nephrology Hospital, Ningbo, PR China; 3The Second School of Clinical Medicine, Southern Medical University, Guangzhou, PR China. *Equal contributors and co-first authors. Received April 22, 2018; Accepted September 12, 2018; Epub January 15, 2019; Published January 30, 2019 Abstract: Objective: The goal of this study was to investigate the relationship between thrombocytopenia and acute kidney injury (AKI) in patients with emphysematous pyelonephritis (EPN). Methods: A retrospective study was con- ducted in three university hospitals, and early hematological biomarkers were detected to predict the development of AKI in EPN patients. Results: Of 56 EPN patients, 32 (59%) developed AKI. Spearman correlation analysis showed that the nadir platelet count was negatively associated with the peak leukocyte count (r=-0.354, P<0.001), peak serum creatinine (r=-0.429, P<0.001), peak blood urea nitrogen (r=-0.317, P<0.001), and the length of hospital stay (r=-0.442, P<0.001). Furthermore, the area under the receiver-operating-characteristic curve (AU-ROC) was used to evaluate the accuracy of thrombocytopenia for the diagnosis of AKI in EPN patients, and the accuracy of nadir platelet count (AU-ROC: 0.92, 95% CI: 0.85-0.99, P<0.001) predicted AKI was significantly higher than admis- sion platelet count (AU-ROC: 0.84, 95% CI: 0.73-0.94, P<0.001).
    [Show full text]
  • Effects of Bodybuilding Supplements on the Kidney
    Ali et al. BMC Nephrology (2020) 21:164 https://doi.org/10.1186/s12882-020-01834-5 RESEARCH ARTICLE Open Access Effects of bodybuilding supplements on the kidney: A population-based incidence study of biopsy pathology and clinical characteristics among middle eastern men Alaa Abbas Ali1, Safaa E. Almukhtar2†, Dana A. Sharif3†, Zana Sidiq M. Saleem4†, Dana N. Muhealdeen1 and Michael D. Hughson1* Abstract Background: The incidence of kidney diseases among bodybuilders is unknown. Methods: Between January 2011 and December 2019, the Iraqi Kurdistan 15 to 39 year old male population averaged 1,100,000 with approximately 56,000 total participants and 25,000 regular participants (those training more than 1 year). Annual age specific incidence rates (ASIR) with (95% confidence intervals) per 100,000 bodybuilders were compared with the general age-matched male population. Results: Fifteen male participants had kidney biopsies. Among regular participants, diagnoses were: focal segmental glomerulosclerosis (FSGS), 2; membranous glomerulonephritis (MGN), 2; post-infectious glomeruonephritis (PIGN), 1; tubulointerstitial nephritis (TIN), 1; and nephrocalcinosis, 2. Acute tubular necrosis (ATN) was diagnosed in 5 regular participants and 2 participants training less than 1 year. Among regular participants, anabolic steroid use was self- reported in 26% and veterinary grade vitamin D injections in 2.6%. ASIR for FSGS, MGN, PIGN, and TIN among regular participants was not statistically different than the general population. ASIR of FSGS adjusted for anabolic steroid use was 3.4 (− 1.3 to 8.1), a rate overlapping with FSGS in the general population at 2.0 (1.2 to 2.8). ATN presented as exertional muscle injury with myoglobinuria among new participants.
    [Show full text]
  • An Unusual Cause of Glomerular Hematuria and Acute Kidney Injury in a Chronic Kidney Disease Patient During Warfarin Therapy Clara Santos, Ana M
    11617 14/5/13 12:11 Página 400 http://www.revistanefrologia.com casos clínicos © 2013 Revista Nefrología. Órgano Oficial de la Sociedad Española de Nefrología An unusual cause of glomerular hematuria and acute kidney injury in a chronic kidney disease patient during warfarin therapy Clara Santos, Ana M. Gomes, Ana Ventura, Clara Almeida, Joaquim Seabra Department of Nephrology. Centro Hospitalar Vila Nova de Gaia. Vila Nova de Gaia (Portugal) Nefrologia 2013;33(3):400-3 doi:10.3265/Nefrologia.pre2012.Oct.11617 ABSTRACT Un caso inusual de hematuria glomerular y fracaso renal agudo en un paciente con enfermedad renal crónica Warfarin is a well-established cause of gross hematuria. durante terapia con warfarina However, impaired kidney function does not occur RESUMEN except in the rare instance of severe blood loss or clot La warfarina es una causa muy conocida de hematuria ma- formation that obstructs the urinary tract. It has been croscópica. Sin embargo, el deterioro de la función renal no ocurre salvo en el caso inusual de gran pérdida de sangre o recently described an entity called warfarin-related formación de coágulos que obstruyen el tracto urinario. Re- nephropathy, in which acute kidney injury is caused by cientemente se ha descrito una entidad denominada nefro- glomerular hemorrhage and renal tubular obstruction patía relacionada con la warfarina en la que el fracaso renal by red blood cell casts. We report a patient under agudo es provocado por hemorragia glomerular y obstruc- warfarin treatment with chronic kidney disease, ción tubular renal por cilindros de glóbulos rojos. Exponemos macroscopic hematuria and acute kidney injury.
    [Show full text]
  • Acute Kidney Injury in Urology Patients: Incidence, Causes and Outcomes
    Nephro Urol Mon. 2013 November; 5(5): 955-61. DOI: 10.5812/numonthly.12721 Research Article Published online 2013 November 13. Acute Kidney Injury in Urology Patients: Incidence, Causes and Outcomes 1 1 2,3 2,3,* Giacomo Caddeo , Simon T. Williams , Christopher W. McIntyre , Nicholas M. Selby 1Department of Urology, Royal Derby Hospital, Derby, UK 2Department of Renal Medicine, Royal Derby Hospital, Derby, UK 3Division of Medical Sciences and Graduate Entry Medicine, School of Medicine, University of Nottingham, Nottingham, UK *Corresponding author : Nicholas M. Selby, Department of Renal Medicine, Royal Derby Hospital, Uttoxeter Road, DE22 3NE, Derby, UK. Tel:+44-01332340131, Fax: +44-01332789352, E-mail: [email protected]. Received: ; Accepted: June 5, 2013 June 27, 2013 Background: Acute kidney injury (AKI) is common in hospitalised patients and is associated with high mortality rates. However, the epidemiology of AKI in urology patients may differ due to a higher proportion of post-renal causes and surgical procedures that result in the intentional removal of renal parenchyma. Objectives: We performed a study to examine the incidence, aetiology and outcomes of AKI in a urological population. Patients and Methods: We performed a single-centre observational study including all hospitalised patients who sustained AKI within the Urology Department over an 18 month period. Patients with AKI were prospectively identified by a hospital-wide, electronic AKI reporting system that also allows demographic, hospital admission and co-morbidity data collection. Data regarding aetiology of AKI and details of surgical procedures were added retrospectively by manual case-note search. Results: 587 episodes of AKI occurred in 410 urology patients, giving an overall incidence of 6.7%.
    [Show full text]
  • In-Depth Review AKI Associated with Macroscopic Glomerular Hematuria: Clinical and Pathophysiologic Consequences
    In-Depth Review AKI Associated with Macroscopic Glomerular Hematuria: Clinical and Pathophysiologic Consequences Juan Antonio Moreno,* Catalina Martı´n-Cleary,* Eduardo Gutie´rrez,† Oscar Toldos,‡ Luis Miguel Blanco-Colio,* Manuel Praga,† Alberto Ortiz,* § and Jesu´s Egido* § Summary *Division of Nephrology and Hematuria is a common finding in various glomerular diseases. This article reviews the clinical data on glomerular Hypertension, IIS- hematuria and kidney injury, as well as the pathophysiology of hematuria-associated renal damage. Although Fundacio´n Jime´nez glomerular hematuria has been considered a clinical manifestation of glomerular diseases without real Dı´az, Autonoma consequences on renal function and long-term prognosis, many studies performed have shown a relationship University, Madrid, Spain; †Division of between macroscopic glomerular hematuria and AKI and have suggested that macroscopic hematuria-associated Nephrology and AKI is related to adverse long-term outcomes. Thus, up to 25% of patients with macroscopic hematuria– ‡Department of associated AKI do not recover baseline renal function. Oral anticoagulation has been associated with glomerular Pathology, Instituto de macrohematuria–related kidney injury. Several pathophysiologic mechanisms may account for the tubular injury Investigacio´n Hospital found on renal biopsy specimens. Mechanical obstruction by red blood cell casts was thought to play a role. More 12 de Octubre, Madrid, Spain; and recent evidence points to cytotoxic effects of oxidative stress induced by hemoglobin, heme, or iron released from §Fundacion Renal red blood cells. These mechanisms of injury may be shared with hemoglobinuria or myoglobinuria-induced AKI. Inigo~ Alvarez de Heme oxygenase catalyzes the conversion of heme to biliverdin and is protective in animal models of heme Toledo/Instituto toxicity.
    [Show full text]
  • Unique Proximal Tubular Cell Injury and the Development of Acute
    Fujigaki et al. BMC Nephrology (2017) 18:339 DOI 10.1186/s12882-017-0756-6 RESEARCH ARTICLE Open Access Unique proximal tubular cell injury and the development of acute kidney injury in adult patients with minimal change nephrotic syndrome Yoshihide Fujigaki1*, Yoshifuru Tamura2, Michito Nagura2, Shigeyuki Arai2, Tatsuru Ota2, Shigeru Shibata2, Fukuo Kondo3, Yutaka Yamaguchi3 and Shunya Uchida2 Abstract Background: Adult patients with minimal change nephrotic syndrome (MCNS) are often associated with acute kidney injury (AKI). To assess the mechanisms of AKI, we examined whether tubular cell injuries unique to MCNS patients exist. Methods: We performed a retrospective analysis of clinical data and tubular cell changes using the immunohistochemical expression of vimentin as a marker of tubular injury and dedifferentiation at kidney biopsy in 37 adult MCNS patients. AKI was defined by the criteria of the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guidelines for AKI. Results: Thirteen patients (35.1%) were designated with AKI at kidney biopsy. No significant differences in age, history of hypertension, chronic kidney disease, diuretics use, proteinuria, and serum albumin were noted between the AKI and non- AKI groups. Urinary N-acetyl-β-D-glucosaminidase (uNAG) and urinary alpha1-microglobulin (uA1MG) as markers of tubular injury were increased in both groups, but the levels were significantly increased in the AKI group compared with the non- AKI group. The incidence of vimentin-positive tubules was comparable between AKI (84.6%) and non-AKI (58.3%) groups, but vimentin-positive tubular area per interstitial area was significantly increased in the AKI group (19.8%) compared with the non-AKI group (6.8%) (p = 0.011).
    [Show full text]
  • Acute Kidney Injury and Organ Dysfunction: What Is the Role of Uremic Toxins?
    toxins Review Acute Kidney Injury and Organ Dysfunction: What Is the Role of Uremic Toxins? Jesús Iván Lara-Prado 1 , Fabiola Pazos-Pérez 2,* , Carlos Enrique Méndez-Landa 3, Dulce Paola Grajales-García 1, José Alfredo Feria-Ramírez 4, Juan José Salazar-González 5, Mario Cruz-Romero 2 and Alejandro Treviño-Becerra 6 1 Department of Nephrology, General Hospital No. 27, Mexican Social Security Institute, Mexico City 06900, Mexico; [email protected] (J.I.L.-P.); [email protected] (D.P.G.-G.) 2 Department of Nephrology, Specialties Hospital, National Medical Center “21st Century”, Mexican Social Security Institute, Mexico City 06720, Mexico; [email protected] 3 Department of Nephrology, General Hospital No. 48, Mexican Social Security Institute, Mexico City 02750, Mexico; [email protected] 4 Department of Nephrology, General Hospital No. 29, Mexican Social Security Institute, Mexico City 07910, Mexico; [email protected] 5 Department of Nephrology, Regional Hospital No. 1, Mexican Social Security Institute, Mexico City 03100, Mexico; [email protected] 6 National Academy of Medicine, Mexico City 06720, Mexico; [email protected] * Correspondence: [email protected]; Tel.: +52-55-2699-1941 Abstract: Acute kidney injury (AKI), defined as an abrupt increase in serum creatinine, a reduced urinary output, or both, is experiencing considerable evolution in terms of our understanding of the pathophysiological mechanisms and its impact on other organs. Oxidative stress and reactive oxygen species (ROS) are main contributors to organ dysfunction in AKI, but they are not alone. The precise mechanisms behind multi-organ dysfunction are not yet fully accounted for.
    [Show full text]
  • Acute Kidney Injury As a Risk Factor for Chronic Kidney Disease
    Acute Kidney Injury as a risk factor for Chronic Kidney Disease KDIGOAlan Cass, MBBS FRACP PhD Menzies School of Health Research Darwin, Australia Global burden of kidney disease KDIGO Jha et al – Lancet 2013 Kidney Disease: Improving Global Outcomes Globalization and kidney disease KDIGO White et al – WHO Bulletin 2008 Kidney Disease: Improving Global Outcomes Kidney disease – winning the war? Is incidence falling in high-income countries? KDIGO Kidney Disease: Improving Global Outcomes Ageing population 1970 KDIGO Kidney Disease: Improving Global Outcomes Ageing population 2010 KDIGO Kidney Disease: Improving Global Outcomes Ageing population 2050 KDIGO Kidney Disease: Improving Global Outcomes Ageing across Asia-Pacific region 2009 2050 Country 15-59:60+ Rank Country 15-59:60+ Rank Japan 1.92 1 Japan 1.01 1 Australia 3.24 2 USA 3.45 3 Hong Kong 3.97 4 Singapore 4.51 5 S. Korea 4.51 6 Taiwan 4.75 7 China KDIGO5.71 8 Vietnam 7.63 9 Kidney Disease: Improving Global Outcomes Ageing across Asia-Pacific region 2009 2050 Country 15-59:60+ Rank Country 15-59:60+ Rank Japan 1.92 1 Japan 1.01 1 Australia 3.24 2 Taiwan 1.14 2 USA 3.45 3 S. Korea 1.17 3 Hong Kong 3.97 4 Singapore 1.24 4 Singapore 4.51 5 Hong Kong 1.25 5 S. Korea 4.51 6 China 1.73 6 Taiwan 4.75 7 Australia 1.82 7 China KDIGO5.71 8 USA 2.03 8 Vietnam 7.63 9 Vietnam 2.13 9 Kidney Disease: Improving Global Outcomes Increasing burden of diabetes KDIGO Kidney Disease: Improving Global Outcomes Coming wave of obesity in children KDIGO WHO 2010 Kidney Disease: Improving Global Outcomes
    [Show full text]
  • Update and Review of Renal Artery Stenosis
    Disease-a-Month 67 (2021) 101118 Contents lists available at ScienceDirect Disease-a-Month journal homepage: www.elsevier.com/locate/disamonth Update and review of renal artery stenosis ∗ Gates B. Colbert, MD, FASN a, , Graham Abra, MD b,c, Edgar V. Lerma, MD, FACP, FASN, FPSN (Hon) d a Baylor University Medical Center at Dallas, 3417 Gaston Ave, Suite 875, Dallas, TX 75246, USA b Stanford University, Palo Alto, CA, USA c Satellite Healthcare, San Jose, CA, USA d UIC/ Advocate Christ Medical Center, Oak Lawn, IL USA Introduction According to Carey et al., “resistant hypertension (RH) is defined as above-goal elevated blood pressure (BP) in a patient despite the concurrent use of 3 antihypertensive drug classes, com- monly including a long-acting calcium channel blocker, a blocker of the renin-angiotensin sys- tem (RAAS) (angiotensin-converting enzyme inhibitor or angiotensin receptor blocker), and a diuretic”. 1 The causes of RH are: non-adherence with dietary salt restriction, drugs (prescription and non-prescription), obstructive sleep apnea, and secondary hypertension. Secondary hypertension accounts for about 5–10% of all cases of hypertension, whereas pri- mary or essential hypertension accounts for 90%. In a series of 4494 patients referred to hyper- tension specialty clinics, 12.7% had secondary causes overall, of which 35% were associated with occlusive renovascular disease. 2 A more recent series showed that 24% of older subjects (mean age, 71 years) with RH were shown to have significant renal arterial disease, with most cases being caused by atheroscle- rotic disease. 3 However, the syndrome of renovascular hypertension can also result from other less common obstructive lesions (fibromuscular dysplasias, renal artery dissection or infarction, Takayasu arteritis, radiation fibrosis, and renal artery obstruction from aortic endovascular stent grafts).
    [Show full text]